Clinical Trial Search

Primary: Change From Baseline in 24-hour Cough Frequency at 14 Weeks — 17.0; 17.0; 12.6; 10.6 Coughs/hour — p=0.99

Primary: Change in 24-hour Objective Cough Frequency (Log Normalized Percent Change Relative to Placebo) — -0.18; -0.45 coughs/hr — p=0.9942

Primary: Relative Change From Baseline in 24-hour Cough Frequency at Day 21 — -64.92; -9.36 coughs per hour — p=<0.0001

Primary: Change From Baseline in Awake Cough Frequency After 8 Weeks of Treatment. — -7.5; -16.9; -18.5; 0.3 Coughs/hour

Primary: Leicester Cough Questionnaire (LCQ) — 3.2; 2.06 score on a scale — p=.23

Primary: Percent Change in Number of Coughs Per Hour in 24 Hours Following 4 Weeks of Study Treatment — -55.16; -61.08; -65.32; -60.38 percentage change — p=0.9334

Primary: Change From Baseline in 24-hour Cough Count After 12 Weeks of Intervention — 0.56; 0.47; 0.52; 0.64 Ratio btw geoMeans of 24h cough count — p== 0.0345

Primary: Change in Leicester Cough Questionnaire Score — 6.61; 2.07 score on a scale

Primary: ATP Level in Sputum Supernatant — 2313.4; 1804.6 pM

Primary: Change in Cough-Specific Quality of Life Questionnaire — 9.8; 5.8 participants

Primary: Change From Baseline to Week 12 in Awake Objective Cough Frequency — -0.185; -0.192; -0.271; -0.243 coughs per hour (log transformed) — p=0.324

Primary: Change From Baseline in the Leicester Cough Questionnaire (LCQ) Total Score at Week 12 — 4.34; 3.59 Scores on a Scale — p=0.034

Primary: Brainstem Neural Activations to Capsaicin — 0.09; 0.39; -0.14; 0.44 Percentage change in BOLD signal — p==0.0028

Primary: Change in Awake Objective Cough Frequency on Log-transformed Scale - Cohort 1 — 0.56; 0.95; 0.46; 0.95 Log coughs/hour — p=0.0055

Primary: Total Cough Count Over 8 Hours at Visits 1, 2 and 3 (Part A) — 152.7; 192.5 cough count

Primary: Change From Baseline in Awake Objective Cough Frequency After 12 Weeks of Treatment (Day 84) — -0.40; -0.64; -0.65; -0.86 log coughs/hour — p=0.0971

Primary: Leicester Cough Questionnaire — 9.04; 8.86; 12.78; 9.44 Total LCQ Score — p=.014

Primary: Number of Coughs Following Capsaicin Inhalation Challenge at Baseline and Following 30 Days of Treatment With Spiriva (Baseline and 30 Days) — 2.5 coughs per dose of…

Primary: Efficacy of Thalidomide in Suppressing the Chronic Cough of Idiopathic Pulmonary Fibrosis Using the Cough Quality of Life Questionnaire. — 47.3; 55.2; 61.6; 44.5 units…

Primary: Number of Participants Who Experienced an Adverse Event — 9; 2 Participants

Primary: Number of Subjects With Serious Adverse Events — 0; 0 Participants

Primary: Change in Cough Severity — 13.15; 9.54 LCQ scores (baseline to 3 months)

Primary: Change From Baseline in Daytime Objective Cough Frequency — -0.5365; 0.0523 Coughs/hour — p=0.0003

Primary: Number of Participants Who Experienced at Least One Adverse Event (AE) — 79; 82 Participants

Primary: Part A: Cough Frequency Per Hour, Assessed Objectively Over 24 Hours Using VitaloJAK® Cough Recorder — 14.88; 17.30; 12.61; 13.21 coughs/hour

Primary: Cough Frequency Measurement — 6.6; 2.7; 2.5; 12.7 coughs per hour over a 24 hour monitorin

Primary: Change in Cough Quality of Life Questionnaire (CQLQ) Score by Treatment Group — -5.00; -6.00 score on a scale

Primary: Percent Change From Baseline in Average Daily Cough-induced Stress Urinary Incontinence (SUI) Episodes at Week 12 — -41.09; -52.78 Percent Change — p=0.004

Primary: Cough Reflex Sensitivity to Capsaicin in Participants Who Received Gefapixant 100 mg and Placebo (Period 1 & Period 2 Combined) — 3.05; 3.04; 1.72; 1.41 natural log (µM)…

Primary: Number of Coughs — 7.3 Coughs — p=<0.01